James B. Canavan

2.0k total citations
54 papers, 1.2k citations indexed

About

James B. Canavan is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, James B. Canavan has authored 54 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Genetics, 22 papers in Epidemiology and 19 papers in Surgery. Recurrent topics in James B. Canavan's work include Inflammatory Bowel Disease (28 papers), Microscopic Colitis (16 papers) and Immune Cell Function and Interaction (11 papers). James B. Canavan is often cited by papers focused on Inflammatory Bowel Disease (28 papers), Microscopic Colitis (16 papers) and Immune Cell Function and Interaction (11 papers). James B. Canavan collaborates with scholars based in United Kingdom, United States and Ireland. James B. Canavan's co-authors include Graham M. Lord, Nick Powell, Thomas T. MacDonald, Émilie Stolarczyk, Jane K. Howard, Ian Jackson, Julian Parkhill, Alan W. Walker, Yalda Sharifi and R.D. Abeles and has published in prestigious journals such as Blood, Immunity and Gastroenterology.

In The Last Decade

James B. Canavan

50 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James B. Canavan United Kingdom	17	529	357	349	271	189	54	1.2k
Károly Palatka Hungary	19	300 0.6×	220 0.6×	404 1.2×	558 2.1×	179 0.9×	61	1.1k
Aysel Yüce Türkiye	18	174 0.3×	448 1.3×	307 0.9×	186 0.7×	168 0.9×	98	1.3k
Mircea Diculescu Romania	19	163 0.3×	360 1.0×	678 1.9×	340 1.3×	120 0.6×	126	1.4k
Fabrizio Bossa Italy	24	369 0.7×	605 1.7×	683 2.0×	1.0k 3.7×	207 1.1×	94	1.8k
Anita Afzali United States	18	320 0.6×	295 0.8×	552 1.6×	505 1.9×	70 0.4×	84	1.1k
Florence Lacaille France	19	108 0.2×	422 1.2×	431 1.2×	170 0.6×	193 1.0×	63	1.3k
Véred Abitbol France	24	280 0.5×	413 1.2×	727 2.1×	876 3.2×	344 1.8×	66	1.7k
René Fahrner Switzerland	16	152 0.3×	369 1.0×	276 0.8×	68 0.3×	264 1.4×	51	1.0k
P Knoflach Austria	18	159 0.3×	420 1.2×	301 0.9×	320 1.2×	78 0.4×	91	1.5k
Hyoun Woo Kang South Korea	19	295 0.6×	336 0.9×	282 0.8×	190 0.7×	161 0.9×	71	1.2k

Countries citing papers authored by James B. Canavan

Since Specialization

Citations

This map shows the geographic impact of James B. Canavan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Canavan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Canavan more than expected).

Fields of papers citing papers by James B. Canavan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Canavan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Canavan. The network helps show where James B. Canavan may publish in the future.

Co-authorship network of co-authors of James B. Canavan

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Canavan. A scholar is included among the top collaborators of James B. Canavan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Canavan. James B. Canavan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danese, Silvio, et al.. (2023). P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. Journal of Crohn s and Colitis. 17(Supplement_1). i534–i535. 3 indexed citations

East, James E., Remo Panaccione, Simon Travis, et al.. (2023). Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials. Journal of Crohn s and Colitis. 17(8). 1342–1353. 25 indexed citations

Danese, Silvio, Remo Panaccione, María T. Abreu, et al.. (2023). Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. Journal of Crohn s and Colitis. 18(2). 264–274. 26 indexed citations

East, James E., et al.. (2023). Artificial intelligence in inflammatory bowel disease: implications for clinical practice and future directions. Intestinal Research. 21(3). 283–294. 23 indexed citations

Danese, Silvio, et al.. (2023). DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i101–i102. 4 indexed citations

Abreu, María T., Silvio Danese, Douglas C. Wolf, et al.. (2023). 950 LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION. Gastroenterology. 164(6). S–208. 1 indexed citations

Vermeire, Séverine, J F Colombel, David T. Rubin, et al.. (2023). P715 Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i844–i845. 1 indexed citations

Danese, Silvio, et al.. (2023). P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis. Journal of Crohn s and Colitis. 17(Supplement_1). i591–i593. 2 indexed citations

Abreu, María T., Silvio Danese, Douglas C. Wolf, et al.. (2023). Tu1725 EFFECTS OF OZANIMOD ON HISTOLOGIC REMISSION AND MUCOSAL HEALING OVER 3 YEARS OF CONTINUOUS TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS. Gastroenterology. 164(6). S–1096. 1 indexed citations

10.

Williams, Ronald B, et al.. (2022). An audit on adherence to antimicrobial prescribing guidelines during Wave One of the SARS-CoV-2 pandemic. Journal of Hospital Infection. 129. 211–213.

11.

Konnikova, Liza, Gilles Boschetti, Adeeb Rahman, et al.. (2018). High-dimensional immune phenotyping and transcriptional analyses reveal robust recovery of viable human immune and epithelial cells from frozen gastrointestinal tissue. Mucosal Immunology. 11(6). 1684–1693. 25 indexed citations

12.

Mrakotsky, Christine, et al.. (2017). O-003 The Brain as Extraintestinal IBD Manifestation: Are Brain and Cognitive Differences in Pediatric Crohn's Disease Associated with Immune Gene Expression?. Inflammatory Bowel Diseases. 1 indexed citations

13.

Goettel, Jeremy A., Daniel Kotlarz, David W. Illig, et al.. (2017). O-011 Low-dose IL-2 Administration Expands Human Regulatory T Cells in Patients with UC and Humanized Mice and Protects Against Experimental Colitis.. Inflammatory Bowel Diseases. 23. 3 indexed citations

14.

Afzali, Behdad, Henrieta Fazekasova, Cristiano Scottà, et al.. (2013). Comparison of Regulatory T Cells in Hemodialysis Patients and Healthy Controls. Clinical Journal of the American Society of Nephrology. 8(8). 1396–1405. 61 indexed citations

15.

Canavan, James B., Behdad Afzali, Cristiano Scottà, et al.. (2012). A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood. 119(8). e57–e66. 61 indexed citations

16.

Powell, Nick, Alan W. Walker, Émilie Stolarczyk, et al.. (2012). The Transcription Factor T-bet Regulates Intestinal Inflammation Mediated by Interleukin-7 Receptor+ Innate Lymphoid Cells. Immunity. 37(4). 674–684. 272 indexed citations

17.

Afzali, Behdad, Peter Mitchell, Cristiano Scottà, et al.. (2011). Relative Resistance of Human CD4+ Memory T Cells to Suppression by CD4+CD25+ Regulatory T Cells. American Journal of Transplantation. 11(8). 1734–1742. 31 indexed citations

18.

Shawcross, Debbie L., Yalda Sharifi, James B. Canavan, et al.. (2010). Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. Journal of Hepatology. 54(4). 640–649. 198 indexed citations

19.

Jaglal, Susan, Gillian Hawker, Cathy Cameron, et al.. (2010). The Ontario Osteoporosis Strategy: implementation of a population-based osteoporosis action plan in Canada. Osteoporosis International. 21(6). 903–908. 34 indexed citations

20.

Powell, Nick, James B. Canavan, Thomas T. MacDonald, & Graham M. Lord. (2010). Transcriptional regulation of the mucosal immune system mediated by T-bet. Mucosal Immunology. 3(6). 567–577. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact